Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Diflunisal on Deucravacitinib PK
NCT04113668Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of deucravacitinib in plaque psoriasis (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 14 days, Area under the plasma concentration-time curve from time zero to time T up to 14 days and 1 more. Started Oct 2019; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04113668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04113668.